Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Grand Pharma
Pharmaceutical Preparation ManufacturingChinaHKSE: 0512.HK
Last verified 9 months agograndpharma.cn
Grand Pharma, officially known as Grand Pharmaceutical Group Limited, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China (CN). Established in 1998, the company has made significant strides in developing innovative healthcare solutions, focusing on areas such as oncology, anaesthesia, and cardiovascular health.
With a robust operational presence across various regions, Grand Pharma is dedicated to producing high-quality pharmaceutical products that meet stringent international standards. Their core offerings include a diverse range of prescription medications and over-the-counter products, distinguished by their commitment to research and development.
Recognised for its market leadership, Grand Pharma has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to prioritise patient-centric solutions, solidifying its reputation as a trusted name in the global pharmaceutical landscape.
25
DitchCarbon score
-17 vs industry average
Grand Pharma’s score of 25 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Grand Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very High
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2024
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Grand Pharma's reported carbon emissions
Grand Pharma's 2021 carbon emissions were about 276,000 metric tonnes CO2e, inherited from its parent company, Grand Pharmaceutical (China) Co., Ltd. This total comprises approximately 172,000 metric tonnes of Scope 1 emissions and about 104,000 metric tonnes of Scope 2 emissions. The company's climate commitments and specific reduction targets were not available in the provided data.
Assessing Grand Pharma as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Grand Pharma and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Grand Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Grand Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Grand Pharma9 months ago
25
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more